RobertLowskyMD

Hematology • Stanford, CA

Associate Professor, Medicine - Blood & Marrow Transplantation, Stanford University Medical Center

Join to view full profile

Dr. Lowsky is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lowsky's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Education & Training

McGill University Faculty of MedicineClass of 1988

Certifications & Licensure

CA State Medical License 2001 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies Start of enrollment: 2003 Mar 01
Completed
Phase 2
Mixed Chimera Allogeneic Transplantation From Matched Unrelated Donors For The Treatment Of Multiple Myeloma Start of enrollment: 2000 Oct 01
Completed
Not Applicable
Allogeneic Transplantation From Related Haploidentical Donors Start of enrollment: 2000 Aug 01
Completed
Phase 2
TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD Start of enrollment: 2004 Jul 01
Completed
Phase 2
Allo BMT in Advanced Leukemia or High Grade Lymphoma Start of enrollment: 1989 Dec 01
Completed
Not Applicable
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma Start of enrollment: 2007 Jan 01
Terminated
Phase 2
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma Start of enrollment: 2009 May 01
Completed
Phase 2
Combined Blood Stem Cell and Kidney Transplant of One Haplotype Match Living Donor Pairs. Start of enrollment: 2010 Jul 14
Active, not recruiting
Phase 1
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders Start of enrollment: 2011 Mar 01
Completed
Phase 2
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies Start of enrollment: 2012 Jan 01
Completed
Phase 1
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell Start of enrollment: 2011 Dec 01
Completed
Phase 1, Phase 2
Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD Start of enrollment: 2013 Jul 01
Completed
Phase 1
CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS, AL and CML Start of enrollment: 2020 Feb 27
Completed
Phase 2
Kidney and Hematopoietic Cell Transplants Using a Regimen to Promote Hematopoietic Cell Engraftment Start of enrollment: 2022 May 06
Enrolling by invitation
Phase 1
Join now to see all

Publications & Presentations

PubMed

34 citations
Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
Andrew Johnsrud, Juliana Craig, John H. Baird, Jay Y. Spiegel, Lori Muffly
Blood Advances. 2021-11-09
11 citations
Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafo...
Andrew Johnsrud, Abdullah Ladha, Lori Muffly, Parveen Shiraz, Gary Goldstein
Transplantation and Cellular Therapy. 2021-07-01
26 citations
Concordance of peripheral blood and bone marrow measurable residual disease in adult acute lymphoblastic leukemia.
Lori Muffly, Vandana Sundaram, Connie Chen, Ilana R. Yurkiewicz, Eric Kuo
Blood Advances. 2021-08-24

Journal Articles

Review Macrochimerism and Clinical Transplant Tolerance
Samuel Strober, Stephan Busque, Edgar Engleman, Robert Lowsky, John D Scandling, Judith Shizuru, ScienceDirect

Abstracts/Posters

Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classic...
Robert Lowsky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
Robert Lowsky, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Authored Content

Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023

Press Mentions

In Memoriam: Samuel Strober, MDApril 15th, 2022
Samuel Strober, Pioneering Transplantation Immunologist, Dies at 81March 31st, 2022
Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021
Join now to see all

Grant Support

Cell Processing And Cell Distribution CoreNational Heart, Lung, And Blood Institute2010–2011
Gene And Cytokine Expression In Tolerance And GVHDNational Institute Of Allergy And Infectious Diseases2009–2011
Cell Processing And Sample DistributionNational Cancer Institute2007–2011